How big is Bruker Corp.?

As of Jun 18, Bruker Corp. has a market capitalization of $6.57 billion, with net sales of $3.45 billion and a net profit of $78.6 million over the last four quarters.

Market Cap: As of Jun 18, Bruker Corp. has a market capitalization of 6,571.33 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Bruker Corp. reported net sales of 3,446.10 million and a net profit of 78.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,781.20 million and total assets of 5,806.70 million.

What does Bruker Corp. do?

Bruker Corporation designs and manufactures scientific instruments and analytical solutions for the Pharmaceuticals & Biotechnology industry, with recent net sales of $801 million and a market cap of approximately $6.57 billion. Key financial metrics include a P/E ratio of 49.00 and a dividend yield of 33.64%.

Overview:<BR>Bruker Corporation designs and manufactures scientific instruments and analytical and diagnostic solutions in the Pharmaceuticals & Biotechnology industry, categorized as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 801 Million (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 17 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 6,571.33 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 49.00<BR>Dividend Yield: 33.64%<BR>Debt Equity: 1.06<BR>Return on Equity: 7.44%<BR>Price to Book: 3.62<BR><BR>Contact Details:<BR>Address: 40 MANNING RD, BILLERICA MA: 01821<BR>Tel: 1 978 6633660<BR>Fax: 1 978 6635585<BR>Website: https://www.bruker.com/

Should I buy, sell or hold Bruker Corp.?

Who are in the management team of Bruker Corp.?

As of March 2022, Bruker Corp.'s management team includes Dr. Frank Laukien as Chairman, President, and CEO, and Dr. William Linton as Lead Independent Director, along with independent directors Bonnie Anderson, Cynthia Friend, Marc Kastner, and John Ornell.

As of March 2022, the management team of Bruker Corp. includes Dr. Frank Laukien, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Dr. William Linton as the Lead Independent Director, along with independent directors Ms. Bonnie Anderson, Ms. Cynthia Friend, Dr. Marc Kastner, and Mr. John Ornell.

Is Bruker Corp. overvalued or undervalued?

As of June 30, 2025, Bruker Corp. is considered overvalued with a P/E ratio of 49, significantly higher than the peer average of 35.20, and despite a high dividend yield of 32.93%, its financial metrics and year-to-date return of -43.24% compared to the S&P 500's 12.22% indicate unfavorable positioning against its competitors.

As of 30 June 2025, Bruker Corp. has moved from an expensive to a very expensive valuation grade. The company is overvalued, as indicated by its P/E ratio of 49, which significantly exceeds the peer average of 35.20 for similar companies, such as Hologic, Inc. with a P/E of 21.83 and The Cooper Cos., Inc. at 34.28. Additionally, Bruker Corp.'s EV to EBITDA ratio stands at 16.45, which is higher than the industry average, further supporting the overvaluation assessment.<BR><BR>The company's Price to Book Value is 3.68, suggesting that investors are paying a premium for its equity compared to its book value. Despite a high dividend yield of 32.93%, the overall financial metrics indicate that Bruker Corp. is not positioned favorably in comparison to its peers. Furthermore, the stock has underperformed against the S&P 500, with a year-to-date return of -43.24% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued.

Is Bruker Corp. technically bullish or bearish?

As of October 3, 2025, Bruker Corp. shows a mildly bearish technical trend, with key indicators like the weekly MACD and moving averages suggesting weakness, and it has underperformed the S&P 500 significantly over the past year.

As of 3 October 2025, the technical trend for Bruker Corp. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and both the KST and OBV show bearish signals on a weekly and monthly basis. The Bollinger Bands are sideways weekly but mildly bearish monthly, and Dow Theory indicates no trend weekly and mildly bearish monthly. <BR><BR>In terms of performance, Bruker has significantly underperformed the S&P 500 over the past year, with a return of -45.58% compared to the S&P 500's 17.82%. This underperformance is also evident over longer periods, such as the 3-year and 5-year returns. Overall, the current technical stance is mildly bearish, with key indicators suggesting weakness in the stock's momentum.